|
|
|
|
|
1
|
Drug Price/Cost Debate: Coping with Escalating Pricing Pressures |
Nov 2009 |
$2,250.00 |
|
Introduction
Insinuations of profi teering were made against an H1N1 swine flu vaccine manufacturer in the summer of 2009.
As the swine flu epidemic began to take on serious proportions, public scrutiny in the United
more...
Published by: Decision Resources
|
|
|
2
|
Dealmaking and Industry Outlook: Neurological Disease |
Nov 2009 |
$2,250.00 |
|
The plethora of recent reports of new genes and pathways linked to neurological diseases shows that the underlying
causes of these diseases are far from certain; as a result, therapeutic strategies in effect today may
more...
Published by: Decision Resources
|
|
|
3
|
H4-13, Market Access, Pricing, and Reimbursement News in the Third Quarter of 2009 |
Oct 2009 |
$2,250.00 |
|
Introduction:
The third quarter of 2009 saw a heated debate in the United States over healthcare reform, the publication of a
report on a European investigation of the pharmaceutical industry, the election of new governments
more...
Published by: Decision Resources
|
|
|
4
|
Biomarker and Diagnostic Opportunities in Clinical Research for Neurological Diseases |
Oct 2009 |
$2,250.00 |
|
Introduction
Biomarkers and imaging tools are enabling technologies in today’s clinical research efforts for neurological
diseases. Whether to improve upon existing methods for monitoring disease progression or to discover validated
measures to detect diseases earlier
more...
Published by: Decision Resources
|
|
|
5
|
Special Report: The Pandemic Paradigm: Balancing Commercial Opportunities with Public Health Concerns in the Face of A/H1N1 2009 |
Oct 2009 |
$4,500.00 |
|
Introduction
WHO and the European Centre for Disease Prevention and Control (ECDC) are advising countries to prepare
for a more severe second wave of A/H1N1 2009 in the winter of 2009-2010. This advisement could be
more...
Published by: Decision Resources
|
|
|
6
|
Innovation, Health Technology Assessment, and Comparative Effectiveness Research: The Obstacle Course to Market Access |
Sep 2009 |
$2,250.00 |
|
Introduction:
The use of health technology assessment (HTA) is growing steadily in Europe, and the U.S. government
has recently announced $1.1 billion in funding for comparative effectiveness research (CER)
as part of its planned overhaul
more...
Published by: Decision Resources
|
|
|
7
|
Pharmaceutical Pricing and Reimbursement in India |
Sep 2009 |
$2,250.00 |
|
Introduction
Faced with a dramatic slowdown in sales in mature pharmaceutical markets, multinational pharmaceutical companies
are looking to substantially increase their sales in India and other emerging markets. The Indian market
is growing by more
more...
Published by: Decision Resources
|
|
|
8
|
SPECIAL REPORT: Can Innovation Supplant Convention in Sarcoidosis Treatment? |
Sep 2009 |
$4,500.00 |
|
Introduction
“I’d love there to be a better agent,” says a thought leader on the current state of sarcoidosis treatment. Many
sarcoidosis patients require little or no treatment, but patients with chronic disease need a
more...
Published by: Decision Resources
|
|
|
9
|
Rethinking Pharmaceutical R&D: Will New Strategies Yield a Pipeline Payoff? |
Sep 2009 |
$2,250.00 |
|
Introduction
Can radical changes to the structures and strategies of pharmaceutical R&D operations—such as
creating more entrepreneurial environments modeled upon biotech companies—increase their productivity?
Many major companies are reorganizing the research branches of their businesses
more...
Published by: Decision Resources
|
|
|
10
|
Disruption or Advantage? Update on Companion Diagnostics |
Sep 2009 |
$2,250.00 |
|
Introduction
Some naysayers disagree, but we regard companion diagnostics as a win-win scenario for all stakeholders.
Companion diagnostics combines drug and diagnostic test development. The potential for effi cient drug development
is huge because companion
more...
Published by: Decision Resources
|
|
|
11
|
A Global Recession Drives New Business Strategies and Evolving Business Models in the Biopharma Industry |
Sep 2009 |
$2,250.00 |
|
The biotechnology and pharmaceutical sectors as we know them will soon cease to exist. Companies in these
sectors have come face-to-face with the harrowing ordeals of a global recession. Four stresses on the industry
are
more...
Published by: Decision Resources
|
|
|
12
|
The 111th U.S. Congress Tackles Healthcare Reform and the Pharmaceutical Industry |
Sep 2009 |
$2,250.00 |
|
In this report
we feature a commentary by Alex M. Brill, CEO of Matrix Global Advisors and
a research fellow at the American Enterprise Institute, who testifi ed before the U.S.
House Judiciary Committee’s
more...
Published by: Decision Resources
|
|
|
13
|
Biopharma Quarter: Key Trends and Events of the Second Quarter of 2009 |
Sep 2009 |
$2,250.00 |
|
The first Phase 0 trial results, thefirst fruits of Japan’s biosimilar pathway, the first straightforward use of the social
marketing tool Twitter to advance a drug franchise, thefirst moves of the EU to regulate third-party
more...
Published by: Decision Resources
|
|
|
14
|
The Pricing and Reimbursement Environment for Neurology Drugs |
Aug 2009 |
$2,250.00 |
|
Introduction:
Neurological disorders will impose a growing social and financial burden on the major pharmaceutical markets
as the elderly population in these countries increases steadily. Governments and other payers recognize the
pressing need to tackle
more...
Published by: Decision Resources
|
|
|
15
|
Chronic Myelogenous Leukemia: New Targeted Therapies Take Aim at Gleevec |
Aug 2009 |
$2,250.00 |
|
Introduction
Chronic myelogenous leukemia (CML) is a rare blood cancer; nonetheless, CML treatments garner substantial
revenues. Despite recent advances in the treatment of this disease (most notably, targeted therapeutics such as
Novartis’s Gleevec/Glivec [imatinib]), significant
more...
Published by: Decision Resources
|
|
|
16
|
Uncovering Biomarker and Diagnostic Opportunities in Immune and Inflammatory Diseases |
Aug 2009 |
$2,250.00 |
|
Introduction
Despite the robust drug market for immune and infl ammatory diseases and their high prevalence, diagnostics associated
with these diseases do not constitute a large marketplace. Although researchers are working to discover
biomarkers, associate
more...
Published by: Decision Resources
|
|
|
17
|
Neurological Disease: Early-Stage R&D and Dealmaking |
Aug 2009 |
$2,250.00 |
|
Introduction
How can early-stage R&D efforts be positioned to tap the remaining opportunity in the neurology
drug market? Although brimming with potential, neurology drug development is also rife with unique
challenges that many companies and
more...
Published by: Decision Resources
|
|
|
18
|
Monitoring Health Through Novel Technologies: Where Are We with Point-of-Care Diagnostics? |
Aug 2009 |
$2,250.00 |
|
Introduction
The point-of-care (POC) diagnostics segment of the in vitro diagnostics fi eld once largely consisted of glucosemonitoring
devices. With billions of dollars generated in revenue in the United States alone, POC testing has
blossomed
more...
Published by: Decision Resources
|
|
|
19
|
Special Report - The Autism Spectrum Disorders Market: Substantial Opportunity and Unique Challenges |
Aug 2009 |
$4,500.00 |
|
Introduction
An increase in public funding for research and a heightened interest among drug developers suggest that a
breakthrough in autism spectrum disorder (ASD) treatment may be imminent. However, drug development has
been slow, plagued
more...
Published by: Decision Resources
|
|
|
20
|
Market Access, Pricing, and Reimbursement News in the Second Quarter of 2009 |
Aug 2009 |
$2,250.00 |
|
Introduction
The second quarter of 2009 saw steady progress toward healthcare reform in the United States and action in
several of the world’s other major pharmaceutical markets to curb pharmaceutical expenditures. Cost-containment
strategies vary considerably
more...
Published by: Decision Resources
|
|
|
21
|
The Neurology Pipeline: A Strategic Review |
Aug 2009 |
$2,250.00 |
|
Mega-blockbuster status would be quick and sure for any safe, effective agent that prevents the death and
damage of neurons associated with neurodegenerative diseases. The potential of such a neuroprotectant is one
of the motivations
more...
Published by: Decision Resources
|
|
|
22
|
Strategies for Building Early-Stage Pipelines Through External Sources |
Jul 2009 |
$2,250.00 |
|
Introduction
Under tremendous pressure to refuel dwindling development pipelines and improve R&D productivity,
pharmaceutical companies are seeking external sources of products and innovation. Biotech companies
offer valuable technologies, targets, and compounds. Pharma companies best able
more...
Published by: Decision Resources
|
|
|
23
|
Dealmaking and Industry Outlook: Autoimmune and Inflammatory Diseases |
Jul 2009 |
$2,250.00 |
|
Introduction
Better diagnostics, the means to treat earlier stage-disease, disease-modifying therapies, and disease prevention
are the holy grails of autoimmune and infl ammatory disease drug development. However, basic science and
redundant biological pathways are holding
more...
Published by: Decision Resources
|
|
|
24
|
The Psychiatric Disease Pipeline: A Strategic Review |
Jul 2009 |
$2,250.00 |
|
Numbers tell the story in psychiatric disease drug development: almost 300 recognized indications,
28% 12-month prevalence that yields large patient populations, strong 7.5% annual sales growth in
recent years, sustained franchise sales, tolerance for use
more...
Published by: Decision Resources
|
|
|
25
|
Pharmaceutial Pricing and Reimbursement in China |
Jun 2009 |
$2,250.00 |
|
Introduction
With a growth rate of more than 20% per year, the Chinese pharmaceutical market is set to become the third
largest in the world in 2011. A radical healthcare reform package recently unveiled by
more...
Published by: Decision Resources
|
|
|
|
|
|
0 items
